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Objeclives. This study ~mpared the etkct r’ haage; in action 
p~teotial duration versus rmductioa vclocib ou atrial flutter 
cycle length to detenuioe whether tkre i .I Lily or .nrtlally 
excitablr gap In atrial flutter. 
tlac&gmd. In an ex4able gap reeutraot cireuil, cycle leagtb 
is proportional toconductlou velocity. Action potential duration is 
not a  direct determinant of cycle leagtb when tbe gap is fully 
excitable. 
Methods. Right atrial q ouophasic action ~tials were re- 
corded from 41 patients during type 1 atrial flutter below aud 
during pbarmaeologlc lntervenths. 
Rest/k, Adenosine (17 f 3  mg [mean t SD]) shortened (p < 
0.001) action potertlal dnratlon but did not &aoge cycle leogth. 
Edraphanium (10 tug) had no significant etfect oa action potential 
durstioa or cycle length. Isoprotereoot (0.03 @kg body weight 
per lain) sltorteaed (p < 0.05) aud procainamide (15 m&g, then 
2 q dmin) prolonged (p < 0.001) action p&entiaI duration add 
- 
Most evidence suggests that the mechanism of type I atria1 
flutter in humans involves a macroreentrant circuit around an 
anatomically or anisotropically defined obstacle with either a 
partially or fully excitable gap (1-8). The tachycardia cycle 
length of an excitable gap reentrant circuit is directly propor- 
tional to conduction velocity. Action potential duration and 
refractoriness are direct determinants of cycle length only if 
the excitable gap is partially rather than fully excitable. In a 
reentrant circuit in which the ulrvefront circulates through 
partially refractory tissue, shortening of action potential dura- 
tion will increase the excitable gap. accelerate cu?duction 
velocity and decreaw the flutter cycle length. In contrast. in a 
reentrant circun m  which thrre is full recovery ofcrit~bility by 
the end of the gap, shortening of action potential duration will 
- 
cycle leugth. Alterations la cyche l ngth HIM not correlated with 
cltan~ in aetloa potentlal duration. PmcalnamIde’s pr&uga- 
tlon of actloll poteotlal du,~tlorl was levemrd by admaark 
~thout aYcaiQ cych- IeogtlL yroesirumidc’s psangah of 
~t~poteUdurathandcyclohgtbrPsspartiaQ~ 
by isoproterenol. Adeilosine’s and lsopmelwlol’s &ortehg of 
ad011 p0tMtlal dtuath and bpmteds shorhbg of cycle 
hgtbwerreti lmcedbypruminaleido. 
c~.AtIialeuttercyclelcogtbisdeteRaiaedpri~ 
byconductioovelacityamldoesnotdepeuddirecQonactiou 
potentialdurathAthliWerhasafullyexcitablegap,mnl 
p-hIddedoesaot~u#gapfhmlfulltoparttal 
excitability. Adenosine and isopmtereool interact rritb pmeela- 
amide such that their ffects arr enheed and procahamlde’s 
effects are diminisbed. 
(I Am Cdl GwdiolI996;27:453- 61) 
not lead :o a change in conduction velocity or tachycardia cycle 
Gngth. Thus, the effect on the atrial flutter cycle length of 
changes in action potential duration compared to alterations in 
conduction velocity will depend on which mechanism of recn- 
try better describes human atrial flutter. 
The objectives of this study were to use pharmacologic 
interventions in humans with atrial flutter 1) to evaluate the 
relative importance of changes in action potentil duration 
compared to arteraticns in conduction velocity on atrial flutter 
cycic leng:h by investigating the effects of adenosine, edropho- 
nium. isoproterenol and procainamide on atrial flutter cycle 
length and monophasic a&n potential duration 2) to deter- 
mint, based on these pharmacologic interventions, whether 
the excitable gap in the atrial flutter reentrant circuit is fully or 
partially excitable, and 3) to examine whether the response to 
adenosine, edrophonium or isoproterenol is altered by pro- 
cainamide. 
study patient.~ The study cohort included 11 patients 
referred for cardioversion of sustained type I atrial flutter. 
Type I atrial flutter was diagnosed according to standard 
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electrocardiographic (ECG) criteria (7.8). Patients with atrial 
rates of 200 to 240 beats/min were included, provided that the 
ECG contained the characteristic sawtooth appearance in the 
inferior leads, and patients with type II atria1 flutter defined as 
an atrial rate greater than 339 beats/min were excluded (8). 
Forty men and one woman (mean [ ?SD] age 69 5 9 years, 
range 51 to 82) were studied. The mean duration of atria1 
rhttter was ‘42 2 86 days (range 2 to 365), and 23 patients 
(56%) had at least one previous episode of atria1 flutter. The 
underlying heart disease was coronary artery disease in 20, 
congestive heart failure in 16, hypertension in 15, valvular 
heart disease in 5. conduction system disease in 5 and heart 
transplantation in 2. No patient was in the immediate period 
after cardiac surgery. By echocardiography, the mean left atrial 
size and left ventricular ejection fraction were 4.5 5 0.8 cm and 
38 ? 15%. respcttiveiy. Class I and III antianhythmic drugs 
were discontinued at least five half-lives before the study; no 
patient was receiving theophylline or dipyridamole or was 
previously treated with amiodarone. Other cardioactive drugs 
were continued, and at the time of the study 20 patients were 
receiving digoxin. 19 calcium channel blocking agents, 18 
angiotensin-converting enzyme inhibitors aud 7 beta- 
adrenerpic blocking agents. All patients were in hemodynam- 
ically stable condition and tolerated drug infusions without 
adverse effects. 
Electropl~ysialo& study. The study was approved by the 
Committee on the Conduct of Human Research of the Vir- 
ginia Commonwealth University. and patients were studied in 
the fasting state after written informed consent had been 
ohtained. A steerable catheter with a pair of silver/silver 
chloride electrodes at the distal tip, and a pair of platinum ring 
electrodes located adjacent to the tip was . ..wd for recording 
atrial monophasic action potentials and bipolar electrograms, 
respectively (EP Technologies). This catheter was inserted 
through the femoral vein to the right atrium in a position 
where a stable monophasic action potential recording was 
obtained. usually in the lateral right atrium OT atrial append- 
age. Monophasic action potential signals obtained with a direct 
current--coupled preamplifier. bipolar intraatrial electrograms 
filtered at 30-500 Hz and three or more ECG leads littered 
at 0.W to 100 Hz were recorded at paper s,pceds of lOO- 
200 mmis. 
Drug studies. After baseline recordings were obtained, 
drug studies were instituted in the following order: 1) in 29 
patients. iwproterenol (0.03 rg,&g body weight per min) was 
infused intravenously fat 5 miu, 2) in 32 p&n;;. cdrophonium 
(IO mg) was given as an intiavenclus bo!us over 1 min: 3) in 34 
patients. adenosine was administered as a rapid holus (mean 
dose 17 z 3 mg.#range a to 18) 5 min after edrophoniut,t: 4) in 
20 pa:ients. procainamide was given intravenously as a loading 
infusion of 15 mgkg (mean dose 1.148 + 190) at a rate not 
cxcccding SO mgmin. followed by a maintenance infusion of 
2 mgmin: 5) 5 m m  after the pr cainamide loadmg mfuston, 
isoproterenol (n = 1X), edrophonium $1 .= i-t) and adenosine 
!n = IS) were again administered as ou’.iined in steps 1 to 3. A 
blood sample was obtained 5 min after :he loading infusion of 
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procainamide was completed for measurement of procain- 
amide and N-acetylprocainamide plasma concentrations 
(11.0 t 3.6 and 1.4 ? 0.6 &ml, respectively). 
Data analysis. The atrial flutter cycle length and monopha- 
sic action potential duration were determined from an average 
of at least 10 cycles at baseline and during each pharmacologic 
intervention (for isoproterenol 5 min after initiation of the 
infusion, for edrophonium 2 to 3 min after the bolus, for 
adenosine during atrioventricular block. for procainamide 
5 min after the loading infusion). The monophasic action 
potential duration was measured from the action potential 
upstroke to the point at which repolarization was 90% com- 
plete. If repolarization was not complete before the next action 
potential, the baseline was defined by the points of intersection 
of the action potential upstroke with the preceding action 
potential and the repolarization phase with the next upstroke. 
A Student two-tailed I test for paired data or a repeated 
measures analysis of variance was used where appropriate. 
When significant F values were demonstrated, the Student- 
Newmann-Reals multiple comparisons test wds used to deter- 
mine significance of individual comparisons. Linear regression 
analysis was used to examine the relationships between 
changes in atrial flutter cycle length and monophasic action 
potential duration. A value of p < 0.05 was considered 
statistically significant, and data are reported as mean value 2 
1 SD. 
Results 
Characteristics of atrial flutter. At baseline before phar- 
macoiogrc intervention, the atria1 flutter cycle lengths ranged 
from 189 to 299 ms (mean 234 2 31) and monophasic action 
potential durations recorded from the right atrium during 
atria1 Butter ranged from 114 to 226 ms (mean 169 t 26). Most 
action potential recordings during atrial Butter demonstrated a 
distinct diastolic resting membrane potential separating each 
action potential (Fig. lA,B). A few episodes of atria1 flutter, 
however, particularly at shorter atrial cycle lengths (less than 
210 ms), demonstrated an apparent absence of electric diastote 
(Fig. 1C). 
Effects of adenosioe, droghonium aad isoprotereaol. The 
effects of adenosine on atrial flutter were rapid in onset. 
occurring within !O to 15 s, persisted for only 20 to 30 s and 
were fully reversible (Fig. 2). Examples of the effect of 
adenosine on atria1 flutter activity are shown in Figure 3. In 34 
patients. sdentxinr shortened (p < OWI) atrial manophasic 
action potential duration by 17 C 16 ms but did not signiii- 
cantly change atria1 flutter cycle length (Table I). No patienr 
dcvrloped atrial fibrillation in response to adcnosine. 
Edrophonium decreased atrial action potential duration in 
21 patients and increased atrial cycle length in 24 patients: 
however, among all 32 patients who received edrophonium. 
ihcx changes were uui st&iiidllv significant (Tabie 1). 
In 29 patients, isoproterenol revenihly shortened IF x 0.05) 
atrial monophasic action potential duration by LO + 9 ms and 
decreased (p < 0.05) atrial flutter cycle length by 7 -+ 4 ms 
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l@ure 1. Surface electrocardiographic (lead aVF) 
and monophasic action potential reawdings from 
the right atrium during episodes of atrial flutter 
from three patient;. The atria1 flutter cycle lengths 
in A, B and C are 260,235 and 206 ms, respectively. 
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(Table 1). Although the mean changes in action potential 
duration and cycle length wete not significantly different from 
each other, the decrease in qcle length was not significantly 
correlated (r = -0.01. p = 0.591) by linear regression analysis 
with the decrease in action potential duration 
E&etsofp- de. In 20 patients, procamamide pro- 
ionged (p < O.OOi) action potential duration by 40 2 18 ms and 
flutter cycle length by 61 ? 20 ms (Table 1). The increase in 
action potential duration induced by procainamide was signif- 
icantly less (p < 0.01) than the increase in cycle length. The 
increase irl cycle length was not significantly correlated (r = 
0.15, p = 0.529) with the change in action potential duration. 
No patient converted to sinus rhythm in response to procain- 
amide. 
Reversal of procainamide’s effects by adenusiw and iso- 
proteronol. In 15 patients, adenosine was given as an intrave- 
nous bolus in the presence of procainamidc. An example of the 
effect on atrial flutter activity of adenosine administered in the 
presence of procainamide is shown in Figure 4. Adenosine 
given during procainamide significantly shortened (p < O.uOl) 
atrial monophasic action potential duration by 40 t 24 ms but 
did not significantly change atrial flutter cycle length (Table 2). 
In 12 patients, adenosine fully reversed. and in 3 patients 
adenosine partialty reversed. the procainamide-induced pro- 
longation of a&r. potential duration. In the 15 patients 
studied. the cr*+ination of procaimunidr and adenkne 
Fire 2. Time course of atria1 Euttrr cycle ler$h (AF CL) and 
monophasic action potential duration (MAPD) changes after 18 mg of 
adenusine (ADD). 
--e-- AFCL 
--!I- MAPD 
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BASELINE 
ADENOSINE Figure 3. Monophasic aclion potential recordings dur- 
ing atria1 flutter from two patients at baseline and during 
adenosine. The atrial cycle lengths and action potential 
durations are above and below the trackgs, respectively. 
B Adenosine shortened the action potentral duration with- 
out signifkantly altering the atrial cycle length. 
ADENOSINE 
significantly shortened (p < 0.05) action ;Mtential duration and 
prolonged (p < 0.001) cycle length compared to baseline 
before both agents (Table 2, Fig. 5). 
Isoproterenol administered to 18 patients in the presence of
proeainamidc significantly shortened (p < 0.05) atrial flutter 
cycle length, i”/ 20 2 7 ms and monophasic action potential 
duration by 25 t 15 ms (Table 2). lsoproterenol did not 
completely reverse the procainamide-induced increases in 
cycle length and action potential duration (Fig. 6). Although 
the increases in cycle length and action potential duration 
induced by procainamide were significantly smaller during 
isoproterenol, the atrial cycle length and action potential 
duration were significantly increased by procainamide both 
before and during isoproterenol (Table 2). 
Table 1. Atrial Monophasic Action Potential Duration and Atrial 
Flutter Cycle Length at Baseline and During Adenosine, 
Edrophonium, Isoproterenol and Procainamide 
Monophasic Action Atrial Rutter 
Potential Duration Qcle Length 
(ms [mean + SD]) (ms [mean + SD]) 
Baseline lb6222 236221 
Ada&w (n = 31) 144 -t 2b* 236t29 
Baseline 168Z26 ?33 2 29 
Edrophonium (n = 32) 165 2 22 237r28 
Baseline 167 z 23 237~32 
Iseprotcrenol (n = 29j 157 2 :3t 231 c 31f 
Baseline 171+23 241+ 33 
,kocainamide (n = 20) 211 + 288 302+48* 
‘p < 0.001 versus baseline. tp < 0.05 versus baseline. 
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Figure 4. Monophasic action potentials 
during atrial flutter at baseline, during pro- 
cainamide and during adenosine in the pres- 
ence of procainamide. The atrial cycle 
lengths and action potential durations are 
above and below the tracings, respectively. 
Adenosine reversed the procainamide- 
induced increase in action potential dura- 
tion (-52 ms) without significantly altering 
the increase in cycle length (-5 ms). 
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Potentiation of effects of adenosine and isoprotereaoi by 
proeaioamide. In 15 patients, adenosine induced a signifi- 
cantly greater (p < 0.081) decrease in monophasic action 
potential duration in the presence of procainamide than at 
baseline in the absence of the antiarrhythmic drug (40 + 24 vs. 
Table 2. Atrial Monophasic Action Potential Duration and Atrial 
Flutter Cycle Length at Baseline. During Adenosine and 
Isoproter&ol Alone and in Combination with Procainamide 
Monophasic Action Atria! Rurter 
Potential Duration Cycle Length 
(ms [mean : SD;) (ms imean = SD]) 
2c1 
I’ 352 
Baseline 
Adenosine 
Pnxainamide 
Pmcainamide + adenoaine 
(n = 15) 
Bzwline 
lsqroterenol 
Pmcainamide 
Pro&urn& + isopioterenot 
(n = 18) 
‘p C 0.05 verSuS baseline. tp < 0.001 versus baseline. $p < O.tMl vems 
pmcainamide. gp < 0.01 versus prczainamide. 
19 2 18 ms) (Fig. 5). This effect of adenosine during pnxain- 
amide remained s$nitirant even when the decrease was nor- 
malized for the preakmsine action potential duration (21 C 
13% vs. 12 2 11% p < 0.01). 
In 18 patients, isoproterenol induced signitkuttly greater 
(p < 0.001) decreases in atrial flutter cycle length (20 t 7 vs. 
7 + 4 ms) and monophasic action potential duration (25 2 15 vs. 
8 2 6 ms) during procainamidc than at baseline (Fig. 6). This 
effect of isoproterenol during procainamide remained signifi- 
cant even when these decreases were normalized for the 
preisoproterenol cycle length (7 _f 2% vs. 3 -t I%, p < 0.05) 
and action potential duration (12 t 69 vs. 5 f 4% p < 0.081). 
The decrease in cycle length induced by isoproterenol in the 
presence of procainamide was significantly correlated (r = 
0.79, p < 0.001) with the increase in cycle length induced hy 
procainamide (Fig. 7) rather than with the changes in action 
potential duratron induced hy isoproterenol or procainamide. 
Discussion 
The findings in this study of type I atrial flutter were the 
following: 1) Adenosine shortened atrial flutter monophasic 
action potential duration but did not change atrial flutter cycle 
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length, edrophonium did not significantly change either action 
potential duration or cycle length, isoproterenol shortened 
both action potential duration and cycle leng:h and procain- 
amide prolonged both action potential duration and cycle 
length. 2) The changes in flutter cycle length induced by 
isoproterenol and procainamide were not correlated with 
changes in atria! action potential duration. 3) Adenosine 
completely reversed the procainamide-induced prolongation 
of action potential duration but had no significant effeci on the 
procainamide-induced increase in cycle length. and isoproter- 
enoi partially ieversed the procainamide-induced prolongation 
of action potential duration and cycle length. 4) Isoprro:ere- 
nol’s shortening of action potential duration and cycle length 
and adenosine’s shortening of action potential duration were 
potentiated by procainamide. 5) The enhanced shortening of 
cycle length by isoproterenol in the presence of procainamide 
Figure 5. Changes in atrial flutter cvcle 
length (AF CL) and monophasic a&on 
potential dwtion (MAPD) induced by 
adenosine (ADO) before (squares) and 
during (triangles) procainamide. 
was related to a reversal oi rhe procainamide-induced prolon- 
gation of cycle length. 
Metbodologic consid-rations. The objective of this inves- 
tigation was to eveLate in patients with atrial flutter the 
relative importance of changes in action potential duration 
compared to alterations in conduction velocity on the atrial 
flutter cycle length. The effects of adenosine, edrophonium and 
isoproterenol, alone and in combination with procainamide, 
were studied. It was hypothesized that these agents would have 
differential effects on atrial refractoriness and conduction 
velocity, and this would be reflected in alterations in monopha- 
sic action potential duration and flutter cycle length. It was 
further postulated that in human atrial flutter, if there is full 
recovery of excitability by the end of the excitable gap, then 
flutter cycle length would be affected by agents that alter 
conduction velocity and would not be directly affected by 
Figure 6. Changes in atrial flutter cvcle 
length (AF CL) and monophasic a&on 
potential duration (MAPD) induced by 
isoproterenol (ISO) before (squares) and 
during (triangtess) prccainamide. 
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Figore 7. Correlation between the decrease in atria1 flutter cycle 
length (AF CL) induced by isoproterenol during procainamide 
and the increase in atrial flutter cycle length induced by pro- 
cainamice alone. 
changes in action potential duration or refractory period. Gn 
the other hand, if there is incomplete or partial recovery of 
excitability during the gap, then atria1 flutter cycle length would 
be affected by changes in either action potential duration or 
conduction velocity. In a partially excitable reentrant circuit, an 
increase in action potential duration OI- a slowing of conduction 
velocity would prolong cycle length, whereas a decrease in 
action potential duration or an acceleration of conduction 
velocity would shorten cycle length. Although previous inves- 
tigations have used pharmacologic agents to characterize the 
properties of the reentrant circuit in animal models of atrial 
flutter, this is the first investigation to utilize this approach 
systematically in human atrial flutter (9-11). 
Effects of adenosine. Adenosine hyperpolarizes resting 
membrane potential and shortens atrial action potential dura- 
tion by activation of a specific outward potassium current but 
does not alter intraatrial conduction velocity (12-14). During 
atrial pacing in humans, adenosine shortens atrial monophasic 
action potential duration and refractoriness. Several studies 
have reported in small series of patients that adenosine given 
during atrial flutter does not change atrial cycle length (15.16). 
The present study corlfirmed these findings in a large group of 
patients with atrial flutter and demonstrated that the lack of 
change in atrial cycle length was associated with a marked 
shortening in atrial action potential duration. 
Effects of isoprbtermol. Isoproterenol presumably de- 
creased atrial action potential duration by stimulating outward 
potassium currents (17). The decrease in action potential 
duration may also be related to changes in cycle length because 
action potential duration is cycle-length dependent (lb). In 
normal myocardial fibers, catecholamines have minimal effects 
‘on conduction velocity, however, in abnormal. partially depo 
larized tissue, isoproterenol speeds conduction by promoting 
hyperpolarization and improving celI to cell coupling (19.20). 
In canine models, using either chronic right atrial enlargement 
or an acute intercaval crush injury, isoproterenol decreases 
atrial flutter cycle length (9,21). In the present study in human 
ISOPROTERENOL daring PROCI?iAMIDE 
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atrial flutter. the decreased atrial flutter qcle length in re- 
sponse to isoproterenol was most likely related to an increase 
in conduction velocity rather than a decrease in action poten- 
tial duration or refractoriness. 
E&cts of edrvphonhmt. Vagal sr;mulation with edropho- 
nium, a cholinesterase inhibitor. did not produce a statistically 
significant change in action potential duration or cycle length. 
In most patients however, edrophonium shortened action 
potential duration and prolonged atrial flutter cycle length by 
3 to 4 ms. In atrial fiberj, cholinergic agonists incrw potas- 
sium conductance. whii shortens atrial action potential dura- 
tion and effective refractory period (22.23). Vagal stimulation 
accelerates the cycle length of tachycardia by 6 to 27 ms in 
leading circle reentry and in anatomic obstacle models (9-11). 
Effects of prac&uml&. The procainamide-induced pro- 
longation of action potential duration was likely secondary to 
blockade of delayed rectifier potassium current and also to the 
increase in atrial cycle length (24.25). Atrial action potential 
duration and the effects of class I antiarrhythmic drugs are 
highly dependent on cycle length (18.25). The increase in atrial 
flutter cycle length induced by procainamide was significantly 
greater than, and was not correlated with, the increase in 
action potential duration. This suggests that the increase in 
atrial flutter cycle length induced by procainamide was not 
related to the increase in action potential duration and was 
likely caused by a s&ing of conduction velocity. Procainamide 
causes dose- and use-dependent block of fast sodium channels. 
which decreases conduct&n velocity in regions exhibiting 
either normal or slowed conduction (24-‘6). In animal mod- 
els, class IA antianltvthmic drugs prolong refractory period. 
slow conduction velocity and increase flutter cycle length by 
30% to 60% (27-31). The findings in the present report are 
consistent with the occlusions of these studies that the 
drug-induced prolongation of ahial flutter cycle length corre- 
lates with changes in atrial conduction velocity rather than in 
refractory period. 
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Reversal of elk& of procaioamide and potentiation of 
effects of adeaosiw and isoproterenol. The mechanism of the 
enhanced effects of adenosine to shorten the atrial action 
potential duration during procainamide may be related to an 
alteration in resting membrane potential. It has been reported 
that the magnitude of adenosine-induced hyperpolatition in 
atrial myocardium depends on the resting membrane potential 
before adenosine; the more depolarized the tissue, the larger 
the hyperpolarixation (13). 
In ventricular tachycardia, the shortening of tachycardia 
cycle length by isoproterenol is greater in the presence than 
absence of procainamide, and this enhanced etfect correlates 
with a greater change in conduction velocity than in refracto- 
riness (32). The present study denonstrates a similar finding in 
atrial flutter, although the magnitude of the decrease in cycle 
length was less. The enhanced shortening of flutter cycle length 
induced by isoproterenol in the presence of procainamide was 
correlated with the increase in cycle length induced by pro- 
cainamide alone. Thus, the mechanism of the potentiation of 
isoproterenol’s effects by procainamide was likely related to 
the slowing of conduction velociry and depression of fast 
inward sodium current induced by procainamide. Altema- 
tively, the weak anticholinergic properties of procainamide 
may have caused a withdrawal of the normal inhibitoty effect of 
background parasympathetic tone on the response to sympa- 
thetic stimulation (i.e., accentuated antagonism) (33). Finally, 
catecholamines improve ceil to cell coupling, and isoprotere- 
nol may have tzversed the effects of procainamide on gap 
junctions or on anisotropic conduction (20.26). 
Pharmacoh@e evideace for mechanism of type I atria1 
tlmt&. Atrial flutter models in animals and studies in humans 
have demonstrated that flutter is caused by a reentrant mech- 
anism (1-11). Depending on the model, the circuit has no 
excitable gap (leading circle reentry), a partially excitable gap 
(Y-shaped atrial incision and atrial enlargement models) or a 
fully excitable gap (sterile peticarditis and atrial crush injury 
models) (9-1134-36). Some human studies suggest that the 
gap is fully excitable, whereas others indic,te that it is only 
partially excitable (4,37-40). On the basis of variations in 
flutter cycle lengths attributed to the QRS complex, Lammets 
et al. (39) and Ravelli et al. (40) recently suggested that type 1 
and type II flutter result from partially excitable gap and 
leading circle reentry, respectively. 
The pharmacologic data from the present study support the 
concept that in human type I atriai flutter there is full recovery 
of excitability during the gap. The finding that adenosine 
signiftcantly shortened atrial action potential duration but did 
not alter cycle length is central to this conclusion. If in atrial 
flutter there is no or a partially excitable gap, then adencsine 
would have shortened the cycle length because the wavefront 
would be accelerated as it progagated through less refractory 
tissue. The data on isoproterenol and procainamide further 
support thii conclusion. Although these agents had combined 
effects on action potential duration and cycle length, the 
changes in cycle length induced by isoproterenol and procain- 
amide were not related to changes in action potential duration. 
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Isoproterenol shortened cycle length by speeding conduct&. 
and procainamide prolonged cycle length by slowing conduc- 
tion rather than by altering action potential duration. Thus, the 
cycle length in human type I atrial llutter is determined 
primarily by conduction velocity rather than by action potential 
duration or refractoriness. 
The present study also suggests that procainamide did not 
convert the fully excitable gap into one that is partially 
excitable. Procainamide increased the flutter cycle length by a 
significantly greater amount than it prolonged the action 
potential duration. Adenosine given during procainamide did 
not alter flutter cycle tength, whereas isoproterenol shortened 
cycle length. Previous animal studies likewise suggest that 
during procainamide there is a persistent gap of full excitability 
within the reentrant circuit and that procainamidc prolongs the 
cycle length by a direct effect to slow conduction of the 
wavefront of excitation (30.31). 
Study limitations. The atrial monophasic action potentials 
were recorded from presumably normal tissue to monitor 
drug-induced changes in atrial gutter and were likely not 
obtained directly from the atrial flutter circuit. The findings 
regarding action potential duration are valid only if these 
measurements were representative of the drugs’ effects on the 
flutter circuit, particularly the local excitable gap and conduc- 
tion velocity in the area of slow conduction. Conduction 
velocity and the circuit’s path length were not measured 
directly, and the latter was assumed to remain constant during 
interventions. The drugs may have affected areas of functional 
block and thus altered the path length, however, small c.ianges 
in path length probably would not alter the current findings or 
conclusions significantly. 
Conclusions. The findings of this study of pharmacologic 
interventions in human type I atrial flutter suggest that the 
atria1 flutter cycle length is determined primarily by conduction 
velocity and does not depend directly on action potential 
duration. These results are also consistent with the concept 
that the atrial flutter reentrant circuit has a fully excitable gap 
in which the wavefront of excitation does not impinge on 
refractory tissue. Procainamide prolongs the atrial flutter cycle 
length by slowi ,&conduction independent of changes in action 
potential &ration and does not convert the excitable gap from 
full to pc:tial excitability. Adenosine and isoproterenol interact 
with procainamide such that their effects are enhanced and the 
effects of procainamide are diminished. 
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